Applied Filters
CMA accuses 4 pharma companies of anti-competitive conduct
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
‘Considerable increase’ in pay-for-delay settlements: FTC report
The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
Eli Lilly releases generic insulin injection
Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
City of Baltimore accuses Janssen of delaying generics
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.
Federal Circuit invalidates Nuvo’s Vimovo patents
The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.
EU adopts SPC manufacturing waiver
The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.
Federal Circuit rules against J&J in Zytiga dispute
The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Clean sweep for AbbVie in Humira litigation
Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
44 states accuse big pharma of price fixing generics market
44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.
E+F patent attorney elevated to partner
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
